Tradipitant in Treatment-resistant Pruritus Associated With Atopic Dermatitis
NCT ID: NCT02651714
Last Updated: 2024-06-13
Study Results
Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.
View full resultsBasic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE2
168 participants
INTERVENTIONAL
2016-01-19
2017-08-04
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Evaluating the Effects of Tradipitant vs. Placebo in Atopic Dermatitis (EPIONE2)
NCT04140695
Efficacy and Tolerability Study of Device, RD047-26 for the Treatment of Mild to Moderate Atopic Dermatitis in Adults
NCT01232985
Study of the Efficacy, Safety, and Tolerability of Serlopitant for Pruritus (Itch) in Atopic Dermatitis
NCT02975206
A Study Investigating the Effect of EDP1815 in the Treatment of Mild, Moderate and Severe Atopic Dermatitis
NCT05121480
Phase 2a Study to Assess the Efficacy,Safety and Tolerability of GIA632 in Adult Participants With Moderate to Severe Atopic Dermatitis
NCT07220577
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
QUADRUPLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Tradipitant
Oral
Tradipitant
Placebo
Oral
Placebo
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Tradipitant
Placebo
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Diagnosed with atopic dermatitis
* Suffering from chronic pruritus with pruritus being actively present
Exclusion Criteria
* Participation in a previous tradipitant (LY686017 or VLY-686) trial
* Anyone affiliated with the site or sponsor and/or anyone who may consent under duress
* Any other sound medical reason as determined by the Investigator including any condition which may lead to an unfavorable risk-benefit of study participation, may interfere with study compliance or may confound study results
18 Years
65 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Vanda Pharmaceuticals
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Vanda Investigational Site
Encinitas, California, United States
Vanda Investigational Site
Encino, California, United States
Vanda Investigational Site
Lomita, California, United States
Vanda Investigational Site
San Diego, California, United States
Vanda Investigational Site
San Diego, California, United States
Vanda Investigational Site
Miami, Florida, United States
Vanda Investigational Site
Miami, Florida, United States
Vanda Investigational Site
Ormond Beach, Florida, United States
Vanda Investigational Site
Columbus, Georgia, United States
Vanda Investigational Site
Plainfield, Indiana, United States
Vanda Investigational Site
Crowley, Louisiana, United States
Vanda Investigational Site
St Louis, Missouri, United States
Vanda Investigational Site
Las Vegas, Nevada, United States
Vanda Investigational Site
New York, New York, United States
Vanda Investigational Site
New York, New York, United States
Vanda Investigational Site
High Point, North Carolina, United States
Vanda Investigational Site
Wilmington, North Carolina, United States
Vanda Investigational Site
Winston-Salem, North Carolina, United States
Vanda Investigational Site
Portland, Oregon, United States
Vanda Investigational Site
Philadelphia, Pennsylvania, United States
Vanda Investigational Site
Johnston, Rhode Island, United States
Vanda Investigational Site
Charleston, South Carolina, United States
Vanda Investigational Site
Houston, Texas, United States
Vanda Investigational Site
Pflugerville, Texas, United States
Vanda Investigational Site
San Antonio, Texas, United States
Vanda Investigational Site
West Jordan, Utah, United States
Vanda Investigational Site
Seattle, Washington, United States
Vanda Investigational Site
Spokane, Washington, United States
Countries
Review the countries where the study has at least one active or historical site.
Provided Documents
Download supplemental materials such as informed consent forms, study protocols, or participant manuals.
Document Type: Study Protocol
Document Type: Statistical Analysis Plan
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
VP-VLY-686-2102
Identifier Type: -
Identifier Source: org_study_id
NCT02672410
Identifier Type: -
Identifier Source: nct_alias
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.